替罗非班在非ST段抬高性急性冠脉综合征治疗中临床疗效观察

Effect of Tirofiban used in patients with Non-ST-elevation Acute Coronary Syndrome

目的探讨替罗非班治疗非ST段抬高性急性冠脉综合征(NSTE-ACS)的有效性及安全性。方法选取笔者所在医院心内科诊治的72例NSTE-ACS患者,随机分为对照组与观察组,对照组给予常规标准治疗,观察组在常规标准治疗的基础上加用替罗非班治疗。观察两组治疗效果、1个月内发生不良心血管事件、48 h心电图变化情况以及不良反应。结果观察组治疗总有效率为94.45%,明显高于对照组的77.78%,差异有统计学意义(P<0.05);对照组不良心血管事件发生率为33.33%,明显高于观察组的11.11%,差异有统计学意义(P<0.05);两组患者用药前ST段压低程度及T波倒置程度无统计学差异(P<0.05),治疗48 h后观察组上述水平明显低于对照组(P<0.05);两组用药后出血发生率及血小板计数比较差别无统计学意义(P>0.05)。结论替罗非班是一种可以安全、有效地治疗非ST段抬高性急性冠脉综合征的药物。

Objective To observe the efficacy and safety of tirofiban in the treatment of non - ST - elevation acute coronary syndrome（ NSTE - ACS）. Methods 72 patients with NST - ACS were enrolled and 36 were assigned to the observation group and 36 were assigned to the control group. The control group were treated with routine medicine, and the observation group were given tirofiban based on the control group. The effect of treatment and changes of ECG after 48h were observed, the main adverse cardiovascular events （MACE） were observed after 1 month, and adverse drug effect were observed. Results The total effective rate in the observation group was significantly higher than that in the observation group （94. 45%, vs 77. 78） （ P 〈 0. 05 ）. The rate of MACE in the control group was significantly higher than that in the observation group （33.33% vs 11.11% ） （P 〈0. 05）. Before treatment,the degree of ST - segment depression and T wave inversion was no significant difference （ P 〈 0. 05 ）, and that were significantly lower in the observation group than that in the control group after 48 h （ P 〈 0.05 ）. There were no difference of the incidence of bleeding and platelet counts in the two groups （ P 〉 0. 05 ）. Conclusion Tirofiban was safe and effective in treating NSTEACS patients.